AFME.PA stock surged 28.83% intraday to €3.62 on EURONEXT on 02 Mar 2026, driven by concentrated buying and a sharp jump from yesterday’s close of €2.81. Trading volume hit 13,857.00 shares versus an average of 27,900.00, signalling a high-volume mover setup for intraday traders. The move lifts the share well above the 50-day average price of €1.78 and 200-day average of €1.52, while fundamentals still show negative earnings per share of -0.36 and a PE of -7.81.

Intraday flow and liquidity: AFME.PA stock

The immediate market fact is strong liquidity: 13,857.00 shares traded today versus an average 27,900.00, and a relative volume of 6.64, which concentrates price discovery in a narrow time window. That concentrated flow produced a day low of €3.50 and a day high of €3.74, amplifying intraday volatility for AFME.PA stock.

Fundamentals and valuation snapshot: AFME.PA stock analysis

Affluent Medical SA (AFME.PA) reports a market cap of €110,426,855.00 and EPS of -0.36, leaving the trailing PE at -7.81 and price-to-sales at 23.52, metrics that reflect early-stage losses and premium market pricing. Balance-sheet ratios show a current ratio of 1.07 and debt-to-equity of 1.11, underlining capital intensity in medical devices and a leverage profile to monitor.

Technicals and volume signals: AFME.PA stock trading cues

Technicals are strongly bullish in the short term: RSI 75.63 (overbought), ADX 58.65 (strong trend), MACD histogram 0.21, and Bollinger upper band €3.67, supporting momentum but warning of a pullback risk for AFME.PA stock. The on-balance volume and MFI both show heavy accumulation, which validates the high-volume mover status today.

Meyka grade and forecast: AFME.PA stock

Meyka AI rates AFME.PA with a score out of 100: 61.43, Grade B, suggestion HOLD; this grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target of €3.89 and a quarterly target of €3.18, which implies a short-term upside of 7.39% to the monthly figure from the current €3.62; forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context: AFME.PA stock outlook

Catalysts include product regulatory updates and trial data for Kardiozis and implant lines, while key risks are continued negative EPS and high price-to-sales of 23.52, which could widen downside if clinical or reimbursement news is adverse. The Healthcare medical-devices sector shows mixed performance year-to-date, so AFME.PA stock will track peer regulatory outcomes and funding signals.

Intraday trading approach and strategy: AFME.PA stock

For intraday traders, the setup calls for tight risk controls given RSI overbought and ATR 0.34; consider scaled positions and stop-loss near today’s low €3.50 or a volatility-adjusted ATR stop. Watch order book depth and follow volume confirmation before adding exposure to AFME.PA stock.

Final Thoughts

AFME.PA stock recorded a sharp intraday move to €3.62 on EURONEXT on 02 Mar 2026, backed by concentrated volume of 13,857.00 shares and momentum indicators that show strong short-term strength. Fundamentals remain loss-making with EPS -0.36 and negative profitability metrics, and the company’s market cap stands at €110,426,855.00, reflecting high investor bet on product potential rather than earnings today. Meyka AI’s forecast model projects a monthly level of €3.89, an implied short-term upside of 7.39% from the current price, while the yearly projection of €1.76 implies a material longer-term reassessment if growth stalls; forecasts are model-based and not guarantees. We recommend monitoring regulatory or clinical news, order flow, and volume confirmation for intraday moves, and using the Meyka grade (B, HOLD) as one input among fundamentals and technical risk controls. For live order-book updates and alerts see Meyka AFME.PA page. For recent market commentary consult company coverage on Investing.com and competitor comparisons for context source and source. Meyka AI provides this AI-powered market analysis platform insight to help frame trading decisions, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.